These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36854518)

  • 21. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.
    Sabbatini R; Ortega C; Procopio G; Masini C; Galligioni E; Porta C
    Future Oncol; 2013 Jun; 9(6):831-43. PubMed ID: 23718304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices.
    Négrier S
    Oncology; 2012; 82(4):189-96. PubMed ID: 22440948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecularly targeted agents for renal cell carcinoma: the next generation.
    Cowey CL; Hutson TE
    Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axitinib for the treatment of metastatic renal cell carcinoma.
    Parekh H; Griswold J; Rini B
    Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
    Tannir NM; Pal SK; Atkins MB
    Oncologist; 2018 May; 23(5):540-555. PubMed ID: 29487224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
    Yildiz I; Sen F; Basaran M; Ekenel M; Agaoglu F; Darendeliler E; Tunc HM; Ozcan F; Bavbek S
    Jpn J Clin Oncol; 2011 Dec; 41(12):1380-7. PubMed ID: 22013228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal cell carcinoma.
    Rathmell WK; Martz CA; Rini BI
    Curr Opin Oncol; 2007 May; 19(3):234-40. PubMed ID: 17414642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
    Joseph RW; Chatta G; Vaishampayan U
    Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant therapy in renal cell carcinoma.
    Massari F; Di Nunno V; Ciccarese C; Graham J; Porta C; Comito F; Cubelli M; Iacovelli R; Heng DYC
    Cancer Treat Rev; 2017 Nov; 60():152-157. PubMed ID: 28992528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.
    Mantia CM; McDermott DF
    Cancer; 2019 Dec; 125(23):4148-4157. PubMed ID: 31532565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma.
    Liu C; Cao F; Xing W; Si T; Yu H; Yang X; Guo Z
    Int J Hyperthermia; 2019; 36(1):220-228. PubMed ID: 30663911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?
    Bex A; Etto T; Vyth-Dreese F; Blank C; Griffioen AW
    Curr Oncol Rep; 2012 Jun; 14(3):230-9. PubMed ID: 22362358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy for advanced renal cell carcinoma.
    Coppin C; Le L; Porzsolt F; Wilt T
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006017. PubMed ID: 18425931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence.
    Rizzo A; Rosellini M; Marchetti A; Mollica V; Massari F
    Immunotherapy; 2021 Jun; 13(8):685-692. PubMed ID: 33823678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New insights into molecular mechanisms of sunitinib-associated side effects.
    Aparicio-Gallego G; Blanco M; Figueroa A; García-Campelo R; Valladares-Ayerbes M; Grande-Pulido E; Antón-Aparicio L
    Mol Cancer Ther; 2011 Dec; 10(12):2215-23. PubMed ID: 22161785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adverse event profile of new targeted agents for renal cell carcinoma].
    Nozawa M; Uemura H
    Hinyokika Kiyo; 2012 Nov; 58(11):655-7. PubMed ID: 23254796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.